Albireo Z Score
ALBO Stock  USD 44.65 0.06 0.13% 
Albireo  Z Score 
Albireo Z Score Analysis
Albireo Pharma's ZScore is a simple linear, multifactor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..2020  2021  2022  2023 (projected)  
Revenues USD  8.31 M  40.58 M  46.67 M  50.35 M 
Revenues  8.31 M  40.58 M  36.52 M  39.4 M 
Z Score  =  Sum Of   5 Factors 
Current Albireo Pharma Z Score  55.2 
Most of Albireo Pharma's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Albireo Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
 
 
 
 

Albireo Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Albireo Pharma is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since Albireo Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Albireo Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Albireo Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate ZScore one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. ZScore can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with ZScores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a socalled 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition 
In accordance with the company's disclosures, Albireo Pharma has a Z Score of 55. This is much higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The z score for all United States stocks is notably lower than that of the firm.
Albireo Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Albireo Pharma's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Albireo Pharma could also be used in its relative valuation, which is a method of valuing Albireo Pharma by comparing valuation metrics of similar companies.Albireo Pharma is currently under evaluation in z score category among related companies.
Albireo Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Albireo Pharma from analyzing Albireo Pharma's financial statements. These drivers represent accounts that assess Albireo Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Albireo Pharma's important valuation drivers and their relationship over time.
2018  2019  2020  2021  2022  2023 (projected)  
Net Income Per Employee  (1.18 M)  (1.14 M)  (1.19 M)  (261.77 K)  (301.03 K)  (324.8 K)  
Revenue Per Employee  326.67 K  175.2 K  92.06 K  312.15 K  358.97 K  360.48 K  
Average Assets  199.19 M  172.87 M  240.71 M  266.95 M  307 M  331.23 M  
Earnings Before Interest Taxes and Depreciation Amortization EBITDA  (41.21 M)  (57.32 M)  (96.07 M)  (19.8 M)  (22.77 M)  (24.57 M)  
Earnings Before Interest Taxes and Depreciation Amortization USD  (41.21 M)  (57.29 M)  (96.08 M)  (19.82 M)  (17.84 M)  (19.25 M)  
Earnings before Tax  (46.09 M)  (62.72 M)  (107.63 M)  (34.03 M)  (30.63 M)  (33.04 M)  
Average Equity  142.23 M  105.98 M  148.89 M  154.69 M  177.89 M  191.93 M  
Enterprise Value  120.02 M  179.83 M  446.4 M  196.32 M  225.76 M  181.22 M  
Free Cash Flow  (26.85 M)  (53.46 M)  (101.11 M)  (108.02 M)  (97.22 M)  (99.78 M)  
Invested Capital  (8.5 M)  (2.96 M)  1.41 M  1.34 M  1.21 M  1.3 M  
Invested Capital Average  (5.73 M)  (3.27 M)  2.73 M  (872 K)  (784.8 K)  (846.76 K)  
Market Capitalization  293.62 M  322.49 M  715.59 M  449 M  516.35 M  557.11 M  
Tangible Asset Value  168.21 M  147.81 M  268.35 M  284.79 M  327.51 M  353.37 M  
Working Capital  154.82 M  122.88 M  236.58 M  223.58 M  257.12 M  277.42 M 
Albireo Fundamentals
Return On Equity  (0.93) %  
Return On Asset  (0.25) %  
Profit Margin  (2.29) %  
Operating Margin  (2.15) %  
Current Valuation  259.98 M  
Shares Outstanding  20.74 M  
Shares Owned by Insiders  3.60 %  
Shares Owned by Institutions  98.42 %  
Number of Shares Shorted  823.31 K  
Price to Earning  (4.16) X  
Price to Book  4.30 X  
Price to Sales  7.35 X  
Revenue  40.58 M  
Gross Profit  39.22 M  
EBITDA  (19.82 M)  
Net Income  (34.03 M)  
Cash and Equivalents  180.97 M  
Cash per Share  9.23 X  
Total Debt  10 M  
Debt to Equity  0.18 %  
Current Ratio  4.49 X  
Book Value Per Share  4.84 X  
Cash Flow from Operations  (107.56 M)  
Short Ratio  1.43 X  
Earnings Per Share  (1.70) X  
Target Price  43.8  
Number of Employees  130  
Beta  0.71  
Market Capitalization  922.94 M  
Total Asset  302.05 M  
Retained Earnings  (171.75 M)  
Working Capital  26.76 M  
Current Asset  28.84 M  
Current Liabilities  2.07 M  
Z Score  55.2  
Net Asset  302.05 M 
About Albireo Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Albireo Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Albireo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Albireo Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Albireo Pharma, Inc., a commercialstage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. Albireo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 130 people.
Albireo Pharma Investors Sentiment
The influence of Albireo Pharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decisionmaking process regarding taking a position in Albireo. The overall investor sentiment generally increases the direction of a stock movement in a oneyear investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Albireo Pharma's public news can be used to forecast risks associated with investment in Albireo. The trend in average sentiment can be used to explain how an investor holding Albireo can time the market purely based on public headlines and social activities around Albireo Pharma. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Albireo Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Albireo Pharma's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Albireo Pharma's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Albireo Pharma.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Albireo Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Albireo Pharma's short interest history, or implied volatility extrapolated from Albireo Pharma options trading.
Pair Trading with Albireo Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Albireo Pharma
  0.79  CVS  CVS Health Corp  Earnings Call Tomorrow  PairCorr 
The ability to find closely correlated positions to Albireo Pharma could be a great tool in your taxloss harvesting strategies, allowing investors a quick way to find a similarenough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma  that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.
The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between 1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better riskadjusted return on your portfolios.Please continue to Albireo Pharma Piotroski F Score and Albireo Pharma Valuation analysis. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Efficient Frontier module to plot and analyze your portfolio and positions against riskreturn landscape of the market..
Complementary Tools for Albireo Stock analysis
When running Albireo Pharma price analysis, check to measure Albireo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Albireo Pharma is operating at the current time. Most of Albireo Pharma's value examination focuses on studying past and present price action to predict the probability of Albireo Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Albireo Pharma's price. Additionally, you may evaluate how the addition of Albireo Pharma to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on binary analysis strategy of nine different fundamentals  
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities  
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk  
Share Portfolio Track or share privately all of your investments from the convenience of any device  
Portfolio Backtesting Avoid underdiversification and overoptimization by backtesting your portfolios 
Is Albireo Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Albireo Pharma. If investors know Albireo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Albireo Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization 922.9 M  Quarterly Revenue Growth 1.683  Return On Assets (0.25)  Return On Equity (0.93) 
The market value of Albireo Pharma is measured differently than its book value, which is the value of Albireo that is recorded on the company's balance sheet. Investors also form their own opinion of Albireo Pharma's value that differs from its market value or its book value, called intrinsic value, which is Albireo Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Albireo Pharma's market value can be influenced by many factors that don't directly affect Albireo Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Albireo Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Albireo Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Albireo Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.